Laerdal Million Lives Fund is an early-stage venture capital fund backed by the Laerdal family and its operating companies that invests in disruptive, data-driven healthcare technologies improving care delivery, access, education, and outcomes. Its mission is to help save one million more lives every year by 2030.
80% of their portfolio is in Healthcare. Average disclosed round size is $29.4M (across 17 rounds with reported amounts).
Portfolio
13
Fund Size
$100M
Top Stage
Series B
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
20 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Boulder Care | Series C | — | May 2024 |
 Avive Solutions | Growth | $56.5M | Apr 2024 |
 Avive | Growth | $56.5M | Apr 2024 |
| Avive | Growth | $56.5M | Jan 2024 |
 Cardiosense | Series A | $15.1M | Dec 2022 |
| Boulder Care | Series B | $36M | Jun 2022 |
 Reliance Health | Series B | $40M | Feb 2022 |
 Reliance HMO | Series B | $40M | Feb 2022 |
 Reliance HMO | Series B | $40M | Jan 2022 |
| Reliance Health | Series B | $40M | Jan 2022 |
 Aloe Care | Seed | $5M | May 2021 |
| Aloe Care | Seed | $5M | Apr 2021 |
| Avive Solutions | Unknown | $7M | Jun 2020 |
| Reliance HMO | Series A | $40M | Jan 2020 |
| Avive | Unknown | $7M | Jan 2020 |
 AMOpportunities | Series A | $2.2M | — |
 Sovato | Unknown | $26.5M | — |
 Corflow | Series B | — | — |
 Novocuff | Series A | $26M | — |
| CCorFlow Therapeutics | Series B | — | — |
Top Co-Investors
P1 Ventures5 shared
General Atlantic5 shared
Picus Capital5 shared
Y Combinator4 shared
AAIC3 shared
Broadview Ventures3 shared
RC Capital3 shared
Health Catalyst Capital3 shared
Springbank Collective2 shared
City Light Capital2 shared
415 Capital2 shared
Wellington Management2 shared
Monte Carlo Capital2 shared
Rock Health2 shared
Gaingels2 shared
First Round Capital2 shared
Partech Africa1 shared
AAIC Investment1 shared
Wildcat Capital Management1 shared
University of Chicago1 shared
Last updated: 20 October 2026